New Tool: ProSource
Checkout our packaging and processing solutions finder, ProSource.
Start Your Search

Sterility Issues Cause Glaucoma Medication Recall

The company identified the problem during its own routine quality control procedures.

Getty Images

According to a recent FiercePharma article, Canada’s largest  generic drugmaker Apotex has issued a voluntary recall of six batches of its glaucoma medication brimonidine tartrate ophthalmic solution due to concerns about potential contamination during the manufacturing process. In a statement, Apotex detected the sterility issue during its own routine quality control checks, and no adverse events have been reported. 

The company is advising patients to stop using the affected products and to consult with their healthcare providers to determine if an alternative treatment is necessary. The recall affects approximately 200,000 packages of the medication that were distributed across Canada.  The recall follows Apotex's 2023 acquisition by private equity firm SK Capital.

Test Your Supply Chain Smarts
Take Healthcare Packaging's supply chain quiz to prove your knowledge!
Take Quiz
Test Your Supply Chain Smarts
Discover Our Content Hub
Access Healthcare Packaging's free educational content library!
Unlock Learning Here
Discover Our Content Hub